BHVN
- Biohaven Pharmaceutical Holding Company Ltd.
()
Overview
Company Summary
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address neurological diseases and rare disorders.
The company's primary objective is to develop and bring to market novel treatments that have the potential to improve the lives of patients suffering from conditions that currently have limited or no treatment options. Neurological disorders, such as migraines, Alzheimer�s disease, spinocerebellar ataxia, and multiple system atrophy, are among the areas of focus for Biohaven.
Biohaven's approach involves identifying potential therapeutic targets, conducting preclinical and clinical research, and advancing promising drug candidates through various stages of development. The company's team of specialized scientists, clinicians, and researchers collaborate to discover, design, and develop innovative molecules and formulations.
One of Biohaven's most significant achievements is the development of rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist. Rimegepant was approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraines in adults in February 2020, offering a new treatment option for a widespread and debilitating condition.
In addition to its drug development efforts, Biohaven also works on identifying and evaluating promising therapy candidates through strategic partnerships and collaborations with academic institutions, research organizations, and industry partners. These collaborations enable the company to leverage external expertise and resources to accelerate the development of potential therapies.
Overall, Biohaven Pharmaceutical Holding Company Ltd. aims to make a meaningful impact on patients' lives by addressing unmet medical needs in the field of neurological diseases and rare disorders through innovative drug development and strategic collaborations.